Clinical trials: Antibody
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
This phase I trial studies the side effects and best dose of iodine I 131 monoclonal antibody BC8 when given together with fludarabine phosphate and low-dose total-body irradiation followed by donor stem cell transplant and…
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Trial name
- NCT00008177
- Testing
- iodine I 131 monoclonal antibody BC8, total-body irradiation, allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Fred Hutchinson Cancer Center
Relapsed Refractory Multiple Myeloma (RRMM)
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is researching a drug called REGN17372 used with another drug called linvoseltamab (each individually called "study drug" or "study drugs" when combined) in participants with relapsed (when a tumor comes back) or…
- Trial name
- NCT07455851
- Testing
- Linvoseltamab, REGN17372+Linvoseltamab
- Where
- 8 sites in Australia, Greece
- Volunteers
- 150 people
- Sponsor
- Regeneron Pharmaceuticals
Advanced Cancer, Metastatic Cancer
FS120 Phase 1/1b Study in Patients With Advanced Malignancies
This is a Phase 1/1b, multicenter, open label study to evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination with Pembrolizumab, in Subjects with Advanced Malignancies
- Trial name
- NCT04648202
- Testing
- FS120
- Where
- 9 sites in United States, Spain
- Volunteers
- 82 people
- Sponsor
- invoX Pharma Limited
Allergic Asthma
Extracorporeal SPecific IgE Removal From the Plasma of Allergic Asthma Patients (ESPIRA-study)
In this study patients suffering from Immunoglobulin E (IgE) mediated asthma are treated with a method, called immune apheresis, that removes IgE from blood.
- Trial name
- ESPIRA (NCT02096237)
- Testing
- IgE adsorber
- Where
- Austria
- Volunteers
- 14 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
SARS CoV 2 Infection
A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals
This is an open-label study examining the safety and tolerability of sotrovimab, administered in two sequential doses as prophylaxis in immunocompromised patients with impaired humoral immunity against SARS-CoV-2.
- Trial name
- NCT05210101
- Testing
- Sotrovimab
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- Sophia Koo, M.D.
Advanced Solid Tumor
γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors
This study intends to combine the advantages of γδ T cells and PD-1 monoclonal antibody to conduct an exploratory clinical study on the safety and efficacy of PD-1 antibody armored γδ T cells (γδ T-PD-1 Ab cells) in the treatment…
- Trial name
- NCT06404281
- Testing
- γδ T-PD-1 Ab cells
- Where
- China
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Changzhou No.2 People's Hospital
Amyloid, Amyloidosis
Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
The purpose of this study is to test the safety and efficacy of Selinexor and Dexamethasone and see what effects it has on AL amyloidosis.
- Conditions
- Amyloid, Amyloidosis, AL Amyloidosis
- Trial name
- STARR (NCT04984330)
- Testing
- Selinexor, Dexamethasone
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
AL Amyloidosis
Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
The purpose of this study is to examine the tolerance, safety, pharmacokinetics, and possible clinical benefit of the good manufacturing practice (GMP)-grade amyloid fibril-reactive chimeric (Ch) IgG1 mAb 11-1F4 in patients with…
- Trial name
- NCT02245867
- Testing
- Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Glomerulonephritis
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of KP104 in participants with IgAN and C3G. The study will start with enrolling the IgAN cohort.
- Trial name
- NCT05517980
- Testing
- KP104
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Kira Pharmacenticals (US), LLC.
Infant Immunity Response and Immunoglobulin Diversity
Infant Immunity Comparison of Breastfed and Bottlefed Infants
This study will follow 40 healthy, vaginally delivered infants that are primarily (>/- 75%) breast fed and 40 infants that are exclusively formula fed for at least the first 4 months of life from birth until 12 month age.
- Trial name
- NCT02568579
- Testing
- blood sample/ stool sample
- Where
- 3 sites in United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Duke University
Autoimmunity
Autoimmune Endocrine Disease Related Antibodies Before the Start of Immune Checkpoint Inhibitor Therapy
Promising treatments have been added to the oncologist's arsenal in recent years. Treatments that, unlike conventional chemotherapy, do not aim to destroy cancer cells directly, but rather activate the patient's own immune system…
- Trial name
- NCT06993727
- Testing
- Blood sampling
- Where
- 3 sites in Belgium
- Volunteers
- 500 people
- Sponsor
- Laura ICONARU
Autoimmune Diseases
Withdraw Drug in Stable IgG4-Related Disease
Evaluation and prediction of relapse risk after glucocorticoid or immunosuppressant withdrawal in patients with stable IgG4 related disease: a prospective cohort study from china.
- Trial name
- NCT04124861
- Testing
- Drug free, IS monotherapy and GC combined with IS
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Peking Union Medical College Hospital
COVID-19
Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell Impairment
This is a multicenter, randomized controlled trial aiming to investigate the efficacy of intravenous immunoglobulin (IVIG) replacement therapy under the hypothesis that immunoglobulin replacement would have therapeutic effects on…
- Trial name
- NCT06159283
- Testing
- Immunoglobulins
- Where
- South Korea
- Volunteers
- 58 people
- Sponsor
- Jaehoon Ko
COVID-19
Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19
Sotrovimab binds to a conserved epitope on the severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 spike protein outside the receptor-binding motif and has been shown to reduce the risk of hospitalization…
- Trial name
- LUNAR (NCT05305651)
- Testing
- Sotrovimab
- Where
- 8 sites in United Kingdom
- Volunteers
- 217 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer
This is a single-center, randomized, open-label, phase II interventional study. Eligible patients will be randomized 1:1 to receive either Trastuzumab-rezetecan (4.8 mg/kg Q3W) or T-DXd (5.4 mg/kg Q3W) for 8 neoadjuvant cycles.
- Trial name
- NCT07416253
- Testing
- Trastuzumab rezetecan, Trastuzumab deruxtecan
- Volunteers
- 68 people
- Sponsor
- Henan Cancer Hospital
Advanced or Metastatic Breast Cancer
A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-low locally advanced or metastatic BC.
- Trial name
- NCT04742153
- Testing
- MRG002
- Where
- 2 sites in China
- Volunteers
- 66 people
- Sponsor
- Shanghai Miracogen Inc.
Rheumatoid Arthritis
Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.
The purpose of the study was to assess the safety, immunogenicity, and clinical efficacy of adalimumab compared with placebo (during double-blind phase) and to to evaluate the long-term safety and maintenance of efficacy…
- Trial name
- NCT00195702
- Testing
- Adalimumab
- Where
- 87 sites in United States, Canada
- Volunteers
- 619 people
- Sponsor
- Abbott
Rheumatoid Arthritis
VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis
This is a multi-national, multi-centre, placebo-controlled, double-blind, randomized, 4-arm parallel group trial, comparing three different dose levels (80 mg, 160 mg and 320 mg) of veltuzumab to placebo, administered weekly…
- Trial name
- VELVET (NCT01390545)
- Testing
- Veltuzumab
- Where
- 63 sites in United States, Argentina and 9 more
- Volunteers
- 300 people
- Sponsor
- Takeda
Recurrent/Refractory Malignant Lymphoma
A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China
A First-in-human, dose-escalation, dose-expansion phase I clinical study of JS004 in subjects with recurrent/refractory malignant lymphoma in China, to evaluate the safety, tolerbility, PK, immunogenicity,antitumor activity and…
- Trial name
- NCT04477772
- Testing
- JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion, Drug：JS001, Intravenous infusion
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Melanoma
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
The primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS).
- Trial name
- NCT05665595
- Testing
- Pembrolizumab/Vibostolimab, Pembrolizumab
- Where
- 205 sites in United States, Argentina and 24 more
- Volunteers
- 1,594 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.